单价SMAC模拟物BI82作为结核病宿主导向治疗的潜力
该研究通过体外细胞感染实验和小鼠感染模型,评估单价SMAC模拟物BI82对抗分枝杆菌感染的效果。结果显示BI82可抑制巨噬细胞内牛分枝杆菌生长并与利福平协同,在结核患者和健康供者全血中限制结核分枝杆菌生长,其机制涉及降解cIAP1促进感染细胞凋亡。小鼠模型中口服BI82可减少肺脾牛分枝杆菌负荷、减轻肺部病变并增加CD3⁺ T细胞及CD4/CD8比值。
要点
- BI82抑制巨噬细胞内牛分枝杆菌生长,与利福平有协同作用。
- BI82在结核患者和健康供者全血中限制结核分枝杆菌生长。
- 口服BI82在小鼠中减少肺脾荷菌量、减轻肺病变并调节T细胞。
核心结论
- BI82通过凋亡依赖机制对分枝杆菌感染发挥广谱活性,是潜力宿主导向治疗候选。
研究设计与样本
- 采用体外细胞感染实验和小鼠感染模型评估BI82抗分枝杆菌效果。
主要发现
- BI82强效抑制巨噬细胞内牛分枝杆菌生长,并与利福平协同。
- BI82在结核患者和健康供者全血中显著限制结核分枝杆菌生长。
- BI82降解cIAP1,促进感染细胞凋亡,表现为cleaved caspase-3和磷酸化MLKL水平升高。
- 小鼠口服BI82减少肺脾牛分枝杆菌负荷、减轻肺部病变,增加CD3⁺ T细胞并提高CD4/CD8比值。
临床怎么用
- BI82作为宿主导向治疗候选,可能用于结核病辅助治疗,尤其需关注与利福平的协同潜力。
局限性
- 研究主要基于体外细胞和小鼠模型,尚未在人体中验证疗效与安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Tuberculosis (TB) caused by the Mycobacterium tuberculosis complex (MTBC) is the leading cause of death from a single infectious agent worldwide. Current antibiotics fail against drug-resistant strains, highlighting the urgent need for novel therapies. Host-directed therapy (HDT), which enhances host immunity rather than targeting pathogens directly, offers a promising solution. METHODS: We use the in vitro cells infection assays and in vivo mouse infection model to identify the effects of a monovalent second mitochondria-derived activator of caspase (SMAC) mimetic named BI82 against mycobacterial infections. RESULTS: We demonstrate that BI82 potently inhibits Mycobacterium bovis growth in macrophages, while exhibiting synergy with rifampicin. BI82 also significantly restricts M. tuberculosis growth in ex vivo whole-blood assays from both tuberculosis patients and healthy donors. BI82 degrades cellular inhibitor of apoptosis protein 1 (cIAP1), promoting infected cell apoptosis as evidenced by elevated cleaved caspase-3 and phosphorylated mixed lineage kinase domain-like levels. In a mouse model, oral BI82 treatment can reduce M. bovis burden in lungs and spleens, alleviate lung lesions, and increase CD3⁺ T cells with elevated CD4/CD8 ratios. CONCLUSIONS: Our findings reveal that BI82 employs a unique apoptosis-dependent mechanism to exert broad-spectrum activity against mycobacterial infections, positioning it as a promising HDT candidate.
引用
- Ji J, Jiang X, Liao X, et al. A Monovalent SMAC Mimetic as a Potential Host-Directed Therapy for Tuberculosis. J Infect Dis. 2026. PMID: 41554287. doi:10.1093/infdis/jiag031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。